# EDGAR Filing Document

**Accession Number:** 0000846377
**File Stem:** 0001477932-26-001016
**Filing Date:** 2026-2
**Character Count:** 16973
**Document Hash:** d32cc0b26a10c140bfa8c89ffd18852d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-26-001016.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0001477932-26-001016

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260222

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Totaligent, Inc.
- **CENTRAL INDEX KEY:** 0000846377
- **STANDARD INDUSTRIAL CLASSIFICATION:** SHORT-TERM BUSINESS CREDIT INSTITUTIONS [6153]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 800142655
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55122
- **FILM NUMBER:** 26674523

**BUSINESS ADDRESS:**
- **STREET 1:** 2255 GLADES ROAD
- **STREET 2:** SUITE 324A
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 561-988-2621

**MAIL ADDRESS:**
- **STREET 1:** 2255 GLADES ROAD
- **STREET 2:** SUITE 324A
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLTEMP, INC.
- **DATE OF NAME CHANGE:** 20170428

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SOURCE FINANCIAL, INC.
- **DATE OF NAME CHANGE:** 20130225

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WIKI GROUP, INC.
- **DATE OF NAME CHANGE:** 20120316

?xml version='1.0' encoding='ASCII'? totaligent_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): <u>February 22, 2026</u>**

---

| |
|:---|
| **TOTALIGENT, INC.**  |
| **(Exact name of registrant as specified in its charter)**  |

---

---

| | | |
|:---|:---|:---|
| **Delaware**  | **001-41803** | **80-0142655** |
| (State or other <br>jurisdiction of incorporation)  | (Commission <br>File Number)  | (IRS Employer <br>Identification No.)  |

---

---

| | |
|:---|:---|
| **3651 FAU Boulevard, Suite 400**<br>**Boca Raton, Florida** | **33431** |
| (Address of principal executive offices)  | (Zip Code)  |

---

Registrant's telephone number, including area code: **<u>(561) 360-3565</u>**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12b of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange Registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On February 22, 2026, Totaligent, Inc. (the "Company") entered into a Binding Letter of Intent (the "LOI") with GloMed Solutions Limited Liability Company ("GloMed"). The LOI sets forth the principal terms for a proposed joint venture (the "JV") to integrate the Aetherium Medical platform with GloMed's operations and the grant of a call option for the Company to acquire GloMed. GloMed distributes a proven portfolio of advanced biologics and medical devices and has secured distribution through a proprietary network of 20+ key opinion leaders and specialty clinics in the high-growth APAC markets. GloMed has approximately $10 million in annual revenue and $1 million in free cash flow.

Key terms include:

- Formation of the JV, to which GloMed will contribute its infrastructure, expertise, relationships, reputation, and related assets, and the Company will contribute the Aetherium Medical platform, intellectual property, know-how, and related assets.

- GloMed will retain its current baseline income, with all incremental revenue generated through the JV shared at a to-be-determined ratio based on cost structures for scaling.

- Governance of the JV will include a board consisting of three seats, filled by Edward DeFeudis, Don Heath, and Ivan Klarich, with the Company appointing three board seats for strategic control.

- The JV is structured on a contribution basis with no initial cash consideration at closing, targeting commencement of operations approximately four weeks following execution of the LOI.

- Grant of a binding call option to the Company to purchase 100% of the equity (or assets, as mutually agreed) of GloMed, including JV interests, at any time during the one-year period following JV closing, for consideration of $3,000,000 in cash plus the issuance of 15% of the Company's outstanding common stock (or equivalent equity interest) on a post-closing, fully diluted basis. The equity is intended to qualify for favorable tax treatment to the extent possible.

- The transaction is structured with no assumption of liabilities unless expressly agreed.

- The parties intend to negotiate and execute definitive agreements (including joint venture agreement, asset contribution and IP assignment agreements, call option agreement, and other customary documents) within approximately four weeks, targeting a March 22, 2026 JV closing.

The LOI contains binding provisions regarding exclusivity (through April 22, 2026 or earlier termination), confidentiality, expenses, and governing law (Delaware, with certain matters subject to Japanese law). The remaining provisions are non-binding and reflect the parties' intent to proceed in good faith. Closing remains subject to due diligence, execution of definitive agreements, no material adverse change, and other conditions, including, for the call option exercise, completion of a PCAOB-compliant audit.

The foregoing description is qualified in its entirety by reference to the LOI, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.**  | **Description** |
| [10.1](totaligent_ex101.htm) | [Binding Letter of Intent, dated February 22, 2026, between Totaligent, Inc. and GloMed Solutions Limited Liability Company.](totaligent_ex101.htm) |
| 107  | Cover Page Interactive Data File (embedded within the Inline XBRL document).  |

---

2<br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TOTALIGENT, INC.** | **TOTALIGENT, INC.** |
| Date: February 25, 2026 | By:  | */s/ EDWARD C DEFEUDIS* |
|  |  | EDWARD C DEFEUDIS |
|  |  | CEO |

---

3<br>

## Exhibit 10.1

**EXHIBIT 10.1**

**BINDING LETTER OF INTENT**

Date: February 22, 2026

To: Don Heath

Chief Executive Officer

GloMed Solutions Limited Liability Company

2-2-4, Utsukushigaokanishi, Aoba-Ku

Yokohama, 225-0001 Japan

From: Edward C. DeFeudis

Chief Executive Officer

Totaligent, Inc.

3651 FAU Blvd., Suite 400

Boca Raton, FL 33431

Re: Binding Letter of Intent for Joint Venture Formation and Call Option to Acquire GloMed Solutions Limited Liability Company

Dear Mr. Heath:

This Binding Letter of Intent (this "LOI") sets forth the binding agreement and understanding between Totaligent, Inc., a Delaware corporation ("Totaligent" or "Buyer"), and GloMed Solutions Limited Liability Company, a Japanese limited liability company owned and controlled by you (the "Seller" or "GloMed"), regarding the proposed formation of a joint venture to integrate the Aetherium Medical platform with GloMed's operations and the grant of a call option for the acquisition of GloMed (the "Transaction").

**1. Transaction Structure**

GloMed distributes a proven portfolio of advanced biologics and medical devices throughout and has secured distribution through a proprietary network of 20+ key opinion leaders and specialty clinics in the high-growth APAC markets. GloMed has approximately $10 million in annual revenue and $1 million in free cash flow.

Totaligent will form a joint venture (the "JV") with the Seller to combine the Aetherium Medical platform—including the dual-track regulatory strategy, intellectual property, know-how, and commercialization infrastructure (now owned by Totaligent). Together with GloMed's infrastructure, expertise, relationships and reputation his will enable rapid market entry and scaling in Japan and APAC via medical tourism channels.

---

| | | |
|:---|:---|:---|
| **CONFIDENTIAL** | Page 1 of 5 | February 22, 2026 |

---

In connection with the Transaction:

· The JV will commence operations as soon as possible, with a target closing date of approximately four (4) weeks following execution of this LOI.

· The Seller will contribute infrastructure, expertise, relationships and reputation, and related assets. Totaligent will contribute the Aetherium platform, intellectual property, know-how, and related assets.

· **Revenue share**: GloMed will retain its current "Baseline" income. All incremental revenue generated through the JV (above the current baseline) will be shared at a to-be determined ratio, based on how costs are structured for the continued scaling of the JV (see Section 3).

· **Governance**: Totaligent will appoint 3 board seats in the JV entity, providing strategic control. The JV board will consist of three (3) seats, to be filled by Edward DeFeudis, Don Heath, and Ivan Klarich.

· The JV is structured on a contribution basis with no initial cash consideration paid at closing.

Additionally, Buyer will receive a binding call option (the "Call Option") to purchase 100% of the equity (or assets, as mutually agreed) of GloMed, including the JV interests, at any time during the one (1) year period following JV closing (the "Option Period"). The one-year Option Period is designed to provide sufficient time to complete a PCAOB-compliant audit (Paid by Totaligent) of the Japanese operations and any other required regulatory steps without the risk of the acquisition right expiring due to timing delays.

The acquisition will be structured with no assumption of liabilities unless expressly agreed in definitive documents.

**2. Consideration Terms**

Upon exercise of the Call Option, the purchase price shall be $3,000,000 in cash plus the issuance to the Seller of 15% of Totaligent's outstanding common stock (or equivalent equity interest) on a post-closing, fully diluted basis (the "Acquisition Equity"). The cash portion will be funded through Totaligent's equity line and/or other financing, including potential proceeds from a Nasdaq uplisting.

The Acquisition Equity will be structured to qualify for favorable tax treatment to the extent possible and will be subject to standard restrictions, vesting provisions (if applicable), and other customary terms.

---

| | | |
|:---|:---|:---|
| **CONFIDENTIAL** | Page 2 of 5 | February 22, 2026 |

---

**3. Key Definitive Agreements**

The parties will negotiate and execute the following definitive agreements (collectively, the "Definitive Agreements") within approximately four (4) weeks following execution of this LOI (target JV close ~March 22, 2026):

· Joint Venture Agreement (including revenue sharing mechanics, governance, contributions, operations, and protections).

· Asset Contribution and IP Assignment Agreements.

· Call Option Agreement (detailing the one-year exercisable period, exercise procedures, and closing conditions).

· Upon option exercise: Stock Purchase Agreement or Asset Purchase Agreement for the acquisition.

· Any employment/consulting agreements for key personnel (including non-compete, non-solicit, IP assignment, and confidentiality).

· Other customary documents.

If the parties are not able to reach satisfactory definitive terms for this agreement within six (6) weeks following execution of this LOI either party may terminate this LOI with 15 days written notice to the other party.

**4. Representations, Warranties, and Covenants**

In the Definitive Agreements, Seller will provide customary representations and warranties regarding ownership and validity of assets/IP/clinic network, financials, no conflicts, no third-party claims, and authority. Buyer will provide customary representations regarding its authority and capitalization.

**5. Exclusivity**

From the date of this LOI until the earlier of (i) execution of the Definitive Agreements for the JV, (ii) mutual written termination of this LOI, or (iii) April 22, 2026 (the "Exclusivity Period"), Seller agree to deal exclusively with Totaligent regarding the JV and any sale or transfer of GloMed or similar transaction. During the Option Period, Seller will not solicit, negotiate, or entertain offers from third parties for the sale of GloMed.

**6. Confidentiality**

The parties agree to maintain the confidentiality of this LOI and all discussions, due diligence materials, and information exchanged. A separate mutual confidentiality agreement will be executed promptly if not already in place.

**7. Due Diligence**

Buyer will have the right to conduct customary due diligence on GloMed's financials, operations, clinic network, assets, IP, team backgrounds, and related matters during the Exclusivity Period. Seller will provide reasonable access to information and personnel.

---

| | | |
|:---|:---|:---|
| **CONFIDENTIAL** | Page 3 of 5 | February 22, 2026 |

---

**8. Conditions to Closing**

JV closing is subject to satisfactory completion of due diligence, execution of mutually acceptable Definitive Agreements, no material adverse change, approval by Totaligent's board of directors (if required), and any required regulatory approvals (expected to be minimal).

Exercise of the Call Option and acquisition closing will additionally be subject to completion of a PCAOB-compliant audit (or equivalent requirements for Totaligent's financial reporting) and any necessary regulatory or shareholder approvals.

**9. Expenses**

Each party will bear its own expenses related to the Transaction, except as otherwise agreed in the Definitive Agreements.

**10. Governing Law and Termination**

This LOI shall be governed by the laws of the State of Delaware; provided that matters specific to GloMed and the JV may be subject to applicable Japanese law as required. This LOI may be terminated by either party upon written notice if Definitive Agreements for the JV are not executed by the target close date. Sections 5 (Exclusivity), 6 (Confidentiality), 9 (Expenses), and this Section 10 shall survive termination. The Call Option, once granted, shall survive in accordance with its terms.

**11. Binding Nature**

Except for Sections 1 (Transaction Structure – as to intent and key terms, including the Call Option grant), 2 (Consideration Terms – as to intent), 5 (Exclusivity), 6 (Confidentiality), 9 (Expenses), and 10 (Governing Law and Termination), which are binding upon execution, the remainder of this LOI is non-binding and reflects the current intent of the parties to proceed in good faith toward Definitive Agreements.

[SIGNATURE PAGE FOLLOWS]

---

| | | |
|:---|:---|:---|
| **CONFIDENTIAL** | Page 4 of 5 | February 22, 2026 |

---

If the foregoing accurately reflects our mutual understanding, please execute and return a copy of this LOI.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| TOTALIGENT, INC. | TOTALIGENT, INC. |
| By: | /s/ EDWARD C DEFEUDIS |
|  | Edward C. DeFeudis, CEO |
|  | Accepted and Agreed: |
|  | GLOMED SOLUTIONS LIMITED LIABILITY COMPANY |
| By: | /s/ D E HEATH |
|  | Don Heath Title: Chief Executive Officer |
|  | Date: February 22, 2026 |
| Donald Heath, individually ('Principal') | Donald Heath, individually ('Principal') |
| By: | /s/ D E HEATH |
|  | Don Heath Title: Owner and Chief Executive Officer |
|  | Date: February 22, 2026 |

---

---

| | | |
|:---|:---|:---|
| **CONFIDENTIAL** | Page 5 of 5 | February 22, 2026 |

---